BWAY vs NVCR

For growth investors, BrainsWay Ltd.

(BWAY) is the stronger pick with 28. 3% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). BrainsWay Ltd. (BWAY) offers the better valuation at 45. 6x trailing P/E (84. 2x forward), making it the more compelling value choice. Analysts rate BrainsWay Ltd. (BWAY) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, BrainsWay Ltd.

(BWAY) delivered a total return of +291. 0%, compared to -92. 1% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: BWAY returned +195. 9% versus NVCR's +40. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BrainsWay Ltd.

(BWAY) is the lower-risk stock at 1. 58β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 40% more volatile than BWAY relative to the S&P 500. On balance sheet safety, BrainsWay Ltd. (BWAY) carries a lower debt/equity ratio of 9% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BrainsWay Ltd.

(BWAY) is pulling ahead at 28. 3% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: BrainsWay Ltd. grew EPS 300. 0% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, BWAY leads at 24. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

BrainsWay Ltd.

(BWAY) is the more profitable company, earning 14. 6% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BWAY leads at 8. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — BWAY leads at 75. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 111.

0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BrainsWay Ltd.

(BWAY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+195. 9% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BWAY: +195. 9%, NVCR: +40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BWAY is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.